

POSTER PRESENTATION

Open Access

Impact of dendritic cells and adjuvant on the in vivo immunogenicity of HTLV-1 Tax 11-19 epitope in hybrid HLA-A2.1/DTR transgenic mice

Divya Sagar¹, Shet Masih¹, Todd Schell², Saifur Rahman¹, Pooja Jain^{1*}, Zafar K Khan^{1*}

From 16th International Conference on Human Retroviruses: HTLV and Related Viruses Montreal, Canada. 26-30 June 2013

Individually, HLA-A2.1 and CD11c-DTR transgenic mouse strains have been used to investigate the immunopathogenesis of different viruses and have provided important insights into current understanding of hostpathogen interactions during human T-cell leukemia virus type 1 (HTLV-1) infection. Here, these mice enabled the study of the CD8 T-cell immune response against a known MHC class I HLA-A2.1-restricted epitope 11-19 of the viral oncoprotein Tax delivered along with tetanus helper peptide without or with incomplete Freund's adjuvant (IFA) in the absence and presence of dendritic cells (DCs). First, a cross breeding strategy was utilized to generate a HLA-A2.1/DTR hybrid strain that carries an HLA-A2.1 gene and diphtheria toxin receptor gene for in vivo depletion of CD11c+ DCs. Upon in vitro stimulation of splenocytes from immunized mice with autologous bone marrow-derived DCs primed with Tax11-19 antigen, DC-depleted mice showed marked attenuation in the proliferation of CD8+ T-cells when compared with the non DC-depleted mice. Additionally, mice immunized with adjuvant demonstrated a much higher frequency of Tax11-19-specific cells response but overall reduced proliferation compared to the non-adjuvant group. A significantly high serum level of IL-6 coincided with depletion of DCs while a decrease in TGF-β cytokine associated with adjuvant use irrespective of DCs' presence. In conclusion, these studies not only demonstrate that the clinically characterized Tax epitope 11-19 can be a potential candidate for the DC-based anti-HTLV-1 vaccine but also illustrate a broader application of the new HLA-A2.1/DTR-transgenic hybrid

mouse strain as an important tool to investigate DC involvement in human class-I-restricted immune responses.

Authors' details

¹Drexel Institute for Biotechnology and Virology Research, and the Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA, USA. ²Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania. USA.

Published: 7 January 2014

doi:10.1186/1742-4690-11-S1-P72

Cite this article as: Sagar *et al.*: Impact of dendritic cells and adjuvant on the in vivo immunogenicity of HTLV-1 Tax 11-19 epitope in hybrid HLA-A2.1/DTR transgenic mice. *Retrovirology* 2014 11(Suppl 1):P72.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



¹Drexel Institute for Biotechnology and Virology Research, and the Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA, USA



